The AFFINITY study is a global, open-label, phase 2 basket trial evaluating the safety and efficacy of atrasentan, an endothelin receptor antagonist, in patients with proteinuric glomerular diseases including IgA nephropathy, Alport syndrome, diabetic kidney disease and FSGS.
Currently, the FSGS cohort is open for enrollment. ISGD encourages members to consider if this clinical trial might be an option for your FSGS patients. The AFFINITY study is seeking to enroll approximately 20 adult patients with FSGS (age 18 years and older) to participate in the FSGS cohort. Patients will receive oral atrasentan once-daily for 52 weeks.
Trial sites are located in the United States, Australia, South Korea, United Kingdom, Spain and Italy. Patient support for transportation (including air, regional train and ground transport) and lodging can be available for patients in each participating country. The sponsor (Chinook Therapeutics) is also open to accepting new trial sites.
Enrollment is anticipated to close by the end of 2023.
We invite you to find out more about the AFFINITY study and how your patients can connect with a participating site.
Clinicians interested in participating as an investigator in the AFFINITY study should contact firstname.lastname@example.org.
Thank you in advance for your consideration.